focus -WSS

focus

author：focus 2025-10-02 11:08:54 - browse：2

Adobe

The Food and Drug Administration is expected to approve Merck’s drug to treat a rare lung disorder called pulmonary arterial hypertension on Tuesday, making available a novel treatment for a deadly condition that’s long been challenging to treat.

In a large trial published last year, the drug, called sotatercept, exceeded expectations in significantly increasing the distance that patients could walk and cutting the risk that their condition would worsen, that they would die, and that they would need new treatments.

Pulmonary arterial hypertension, or PAH, is estimated to occur in 15 to 50 per million people, mostly in women. It’s characterized by a proliferation of cells in the blood vessels that connect the right side of heart to the lungs, making it harder for blood to pass through and leading the heart to have to work harder to pump blood into the lungs. The disease, which causes difficulty breathing, fatigue and dizziness, has a high mortality rate, with one study finding that one-fifth of patients died at around three years after diagnosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： STAT Summit: How a Chicago ER doctor tackles gun violence

hotspot

focus

hotspot

WSS

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Boston competes with Raleigh

Senate committee scrutinizes Medicare Advantage brokers

Solve the antibiotic resistance crisis with preventive drugs

New clues to why women have higher risk of autoimmune disorders

FTC sues over Novant Health acquisition of two N.C. hospitals

focus

focus

focus

Continuity nursing helped my family in our darkest PICU moments

Merck, Johnson & Johnson CEOs will testify on high drug prices

Medicare proposal to cover medical devices draws a mixed reaction

Lawmakers consider Medicare pay reforms for doctors

Bright Health sells Medicare Advantage business to Molina

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Jerome Adams on the need for new antivirals for Covid

FDA struggles to regulate food additives, sometimes for decades

Drug repurposing or repositioning? The language matters

Investment in vaccine development is lagging, report finds

explore

Philips to halt sales of sleep apnea machines in U.S.

Medicare Advantage insurers face 0.2% cut to 2025 payments

Vertex non

Researchers explore possible ties between long Covid, menopause

NIH confirmation hearing shows politicization of research

First Opinion Podcast: Long Covid needs a new approach

hotspot

focus

hotspot

focus